1035920-14-9Relevant articles and documents
Process development and pilot-plant synthesis of (2-Chlorophenyl)[2- (phenylsulfonyl)pyridin-3-yl]methanone
Kopach, Michael E.,Kobierski, Michael E.,Coffey, D. Scott,Alt, Charles A.,Zhang, Tony,Borghese, Alfio,Trankle, William G.,Roberts, Dilwyn J.,Moynihan, Humphrey,Lorenz, Kurt,Mcnamara, Orla A.,Kissane, Marie,Maguire, Anita R.
scheme or table, p. 1229 - 1238 (2011/04/18)
Routes to (2-chlorophenyl)[2-(phenylsulfonyl)pyridin-3-yl]methanone, 1, an intermediate in the manufacture of NK1-II inhibitor LY686017 are described which produce 1 in >75% yield and 95% purity. A highly selective telescoped ortho lithation/condensation/oxidation process was developed and successfully scaled to the clinical pilot plant to produce 25 kg of 1. For the pilot-plant campaign, the lithiation step was developed to operate at -50 °C using commercial lithium diisopropylamide (LDA), and the oxidation step employed catalytic TEMPO as the primary and NaOCl as the terminal oxidant. After completion of the pilot-plant campaign second-generation approaches to 1 were developed to improve process greenness where the lithiation and condensation step were operated as warm as -10 °C, the highly efficient AZADO catalyst was used as a substitute for TEMPO in the Anelli-Montanari oxidation, and process mass intensity was reduced 25%.
NOVEL CRYSTALLINE FORMS OF {2-[1-(3,5-BIS-TRIFLUOROMETHYLBENZYL)-5-PYRIDIN-4-YL-1H-[1,2,3]TRIAZOL-4-YL]-PYRIDIN-3-YL}-(2-CHLOROPHENYL)-METHANONE
-
Page/Page column 21-22, (2010/02/11)
The present invention provides novel crystalline forms of {2-[1-(3,5-bistrifluoromethylbenzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]- pyridin-3-yl}-(2-chlorophenyl)-methanone, compositions thereof, intermediates thereof, methods of using the same, processes for making the same, and processes for making intermediates thereof. X-16289
